Literature DB >> 9121765

IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells.

A C Hobeika1, P S Subramaniam, H M Johnson.   

Abstract

Prostate cancer, like other types of cancer, is associated with the loss of cell cycle control, resulting in unregulated growth of cells. We report here on the inhibitory effects of interferon alpha (IFN alpha) on the cell cycle of prostate cancer cells, using the human prostate carcinoma cell line DU145 that has mutations in the tumor suppressor genes pRB, p53 and KAI1. IFN alpha inhibited growth and colony formation of DU145 cells and analysis by flow cytometry suggests that IFN alpha inhibited the progression of these cancer cells from the G1 through S phase of the cell cycle. IFN alpha treatment of DU145 cells reduced cyclin dependent kinase 2 (cdk2) activity. In particular, cyclin E dependent cdk2 activity was inhibited by IFN alpha treatment. IFN alpha treatment, however, did not affect the amount of cdk2 bound to cyclin E. Consistent with this data, IFN alpha was able to induce expression of the kinase inhibitor p21 in DU145 cells. Furthermore, IFN treatment increased the amounts of p21 complexed with cdk2 in these cells. These data support a role for p21 in mediating the antiproliferative action of IFN alpha. The induction of p21 and its growth inhibitory effects in DU145 cells appears independent of p53, pRB and KAI1 status.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121765     DOI: 10.1038/sj.onc.1200939

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  Functional role of p21 during the cellular response to stress.

Authors:  M Gorospe; X Wang; N J Holbrook
Journal:  Gene Expr       Date:  1999

Review 2.  Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Authors:  Martina Musella; Gwenola Manic; Ruggero De Maria; Ilio Vitale; Antonella Sistigu
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

Review 3.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

4.  Inhibition of the glioblastoma cell cycle by type I IFNs occurs at both the G1 and S phases and correlates with the upregulation of p21(WAF1/CIP1).

Authors:  T Tanabe; S L Kominsky; P S Subramaniam; H M Johnson; B A Torres
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

5.  Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors.

Authors:  S Jayachandra; K G Low; A E Thlick; J Yu; P D Ling; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 6.  Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Authors:  P S Moore; Y Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

7.  Basic fibroblast growth factor stimulates cytosolic phospholipase A2, phospholipase C-gamma1 and phospholipase D through distinguishable signaling mechanisms.

Authors:  G Sa; T Das
Journal:  Mol Cell Biochem       Date:  1999-08       Impact factor: 3.396

8.  Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation.

Authors:  A Dicitore; E S Grassi; M O Borghi; G Gelmini; M C Cantone; G Gaudenzi; L Persani; M Caraglia; G Vitale
Journal:  J Endocrinol Invest       Date:  2017-03-01       Impact factor: 4.256

9.  A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon.

Authors:  Maria D Gainey; Mary J Manuse; Griffith D Parks
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells.

Authors:  Claire Hastie; John R Masters; Stephen E Moss; Soren Naaby-Hansen
Journal:  J Biol Chem       Date:  2008-01-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.